Minutes: Steering Board meeting, 4 and 6 January 2021

Meeting with Moderna representatives

Moderna representatives held a comprehensive presentation to the Members of the Steering Board on the:

1. Subcontractor legal documentation,

2. Product release to the EU Member States
   The Company presented the overall manufacturing and release process, outlining the general process overview.

   In this context, Moderna representatives presented details as regards the:
   • shipment;
   • in-country receipt;
   • release of the product;
   • the transport concept;
   • details on the transport equipment trailers and equipment;
   • vaccines transport warehouse to costumer.

3. Estimated delivery schedule
   The representatives of the Company presented a comprehensive table with delivery schedule for each Member State.

   The presentation was followed by an exchange between the Members of the SB and the representatives of the Company.

   The ordinary Steering Board meeting started with a follow-up discussion on Moderna.
Subsequently, the Steering Committee held an in depth discussion on the top-up for Pfizer/Biontech (top up= beyond the additional doses)

The Member States had already expressed a strong interest in the top-up in previous discussions/feedback reflected in the hi a tour de table the Member States were asked once again to confirm their interest in the top-up and indicate the top-up volume each is interested in, as to have a clear picture that would allow the Commission to advance in discussions with the company both on the number of doses and the schedule for the top-up delivery.

The tour de table outlined that the interest of the Member States in the top-up went well beyond the doses, for which the Commission had initially been given the mandate to start exploratory discussions with the company.

The Members also expressed a strong interest for the top-up doses to be delivered as soon as possible, stressing that the calendar proposed during the first exploratory discussions ( ) was not satisfactory enough.

The Members acknowledged that the delivery timeline was directly linked to the number of doses.

Therefore, the Commission was mandated to continue the exploratory talks for an agreement for a much larger top-up volume.

[ ] and [ ] deplored the fact that, despite various calls to the Member States, they had received [ ]. While wanting to ensure solidarity, some Member States expressed concerns that:

(i) [ ]

(ii) [ ] the resubmission of new Order Forms would delay the delivery schedule of the optional doses.

A possible solution that was explored was to satisfy the needs of additional doses of the Member States through [ ]

[ ] pleaded for solidarity in light of the extraordinary circumstances caused by an was reassured of the help from the MSs regarding extra doses.
Exceptional Steering Board - 6th of January

Update and implementation of contracts

The exceptional Steering Board on the 6th of January meeting was organized to continue the discussions on.

During this session, another discussion was held amongst the Member States to accommodate changes in the allocation tables for the optional doses of the Pfizer/BioNTech and Moderna vaccine.

The discussions focused on accommodating the needs of the Member States ( ) that requested their pro-rata allocation from the optional doses from BioNTech/Pfizer after having originally declined any optional volume.

pleaded again for help to the Member States for extra doses, in light of the exceptional circumstances created by the recent . was reassured of the help from the MSs regarding extra doses.